Auxilium Revamps Commercial Strategy For Xiaflex
This article was originally published in The Pink Sheet Daily
Executive Summary
The manufacturer expected Xiaflex to take off as a non-invasive, more effective alternative to hand surgery, but the market has been slow to convert, prompting Auxilium to shift around its commercial organization.
You may also be interested in...
Auxilium Signs Sobi As Pfizer Replacement In Europe
The maker of Xiaflex/Xiapex has found a new commercialization partner in the EU after its first partnership fell apart due to disappointing sales of the drug in those territories.
Xiaflex Sales Still Slow, But Other Indications In The Works
Auxilium’s Xiaflex sales still languish, but its older testosterone product continues to drive growth for the company.
Deals Of The Week: Novartis/Enanta, Ligand/Retrophin, Auxilium/Actelion, Amgen/Dako
A prosaic week in biopharma deal-making leads DOTW to ponder a brain-computer interface specialist’s efforts to apply its technology to patients with severe communication limitations.